Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sareum Holdings PLC (GB:SAR)
LSE:SAR
Sareum Holdings (SAR) Share Price & Analysis
15 Followers
SAR Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range10.00p - 124.50p
Previous Close36.5p
Volume712.44K
Average Volume (3M)1.51M
Market Cap
£39.40M
Enterprise Value36.46M
Total Cash (Recent Filing)£2.94M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta0.35
Next Earnings
Oct 15, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding71,069,416
10 Day Avg. Volume215,749
30 Day Avg. Volume1,513,549
Standard Deviation0.38
R-Squared0.00237
Alpha0.08
Financial Highlights & Ratios
Price to Book (P/B)9.36
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-10.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Sareum Holdings News
PremiumCompany Announcements
Sareum Holdings Reports Promising Phase 1 Results
PremiumCompany Announcements
Sareum Holdings Appoints New Sole BrokerPremiumCompany Announcements
Sareum Holdings Announces Warrant Exercise and Share Issue
PremiumCompany Announcements
Sareum Completes Share Issuance to RiverFortOptions Prices
Currently, No data available
---
Ownership Overview
4.81% Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
95.19% Public Companies and
Individual Investors
SAR FAQ
What was Sareum Holdings PLC’s price range in the past 12 months?
Sareum Holdings PLC lowest share price was 10.00p and its highest was 124.50p in the past 12 months.
What is Sareum Holdings PLC’s market cap?
Currently, no data Available
When is Sareum Holdings PLC’s upcoming earnings report date?
Sareum Holdings PLC’s upcoming earnings report date is Oct 15, 2024 which is in 102 days.
How were Sareum Holdings PLC’s earnings last quarter?
Sareum Holdings PLC released its earnings results on Mar 28, 2024. The company reported -0.036p earnings per share for the quarter, missing the consensus estimate of N/A by -0.036p.
Is Sareum Holdings PLC overvalued?
According to Wall Street analysts Sareum Holdings PLC’s price is currently Overvalued.
Does Sareum Holdings PLC pay dividends?
Sareum Holdings PLC does not currently pay dividends.
What is Sareum Holdings PLC’s EPS estimate?
Sareum Holdings PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sareum Holdings PLC have?
Sareum Holdings PLC has 107,945,786 shares outstanding.
What happened to Sareum Holdings PLC’s price movement after its last earnings report?
Sareum Holdings PLC reported an EPS of -0.036p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -25.862%.
Which hedge fund is a major shareholder of Sareum Holdings PLC?
Currently, no hedge funds are holding shares in GB:SAR
---
Sareum Holdings Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.80%
12-Months-Change
Fundamentals
Return on Equity
-257.72%
Trailing 12-Months
Asset Growth
-41.20%
Trailing 12-Months
Company Description
Sareum Holdings PLC
Sareum Holdings PLC is engaged in drug discovery and development. The company is focused on cancer and autoimmune diseases and licensing them to pharmaceutical and biotechnology companies. The company's drug programs include Checkpoint Kinase 1 (CHK1), Aurora+FLT3 Kinase and Tyrosine Kinase 2- autoimmune diseases (TYK2), Aurora+FLT3 kinase and TYK2 kinase-cancer. Its Chk1 program is the advanced program and shows potency in disease models of lung and colon cancers in combination with chemotherapy; acute myeloid leukemia (AML) and B-cell lymphoma, and head and neck cancers in combination with radiotherapy. TYK2 kinase program focuses on developing a series of TYK2 inhibitors that can be dosed orally against various autoimmune and inflammatory disorders.
---
Technical Analysis
---